DK1492539T3 - Statin-terapi til forögelse af kognitiv funktion - Google Patents

Statin-terapi til forögelse af kognitiv funktion

Info

Publication number: DK1492539T3
Authority: DK; Denmark
Prior art keywords: cognitive function; statin; statin therapy; enhance cognitive; galantamine
Prior art date: 2002-04-02

Application number

DK03745196T

Other languages

English (en)

Inventor

Sean Lilienfeld

Elane M Gutterman

Royston John Glasspool

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-02

Filing date

2003-03-28

Publication date

2006-10-30

2003-03-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2006-10-30 Application granted granted Critical

2006-10-30 Publication of DK1492539T3 publication Critical patent/DK1492539T3/da

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
230000003920 cognitive function Effects 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
206010012289 Dementia Diseases 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
229960003980 galantamine Drugs 0.000 abstract 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Indole Compounds (AREA)

DK03745196T 2002-04-02 2003-03-28 Statin-terapi til forögelse af kognitiv funktion DK1492539T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36928502P	2002-04-02	2002-04-02

Publications (1)

Publication Number	Publication Date
DK1492539T3 true DK1492539T3 (da)	2006-10-30

Family

ID=28675573

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03745196T DK1492539T3 (da)	2002-04-02	2003-03-28	Statin-terapi til forögelse af kognitiv funktion

Country Status (21)

Country	Link
EP (1)	EP1492539B1 (da)
JP (1)	JP2005525391A (da)
KR (1)	KR100986194B1 (da)
CN (1)	CN100528164C (da)
AT (1)	ATE331523T1 (da)
AU (1)	AU2003226753B2 (da)
BR (1)	BR0308293A (da)
CA (1)	CA2480275C (da)
CY (1)	CY1105545T1 (da)
DE (1)	DE60306503T2 (da)
DK (1)	DK1492539T3 (da)
EA (1)	EA013069B1 (da)
ES (1)	ES2268393T3 (da)
IL (2)	IL164317A0 (da)
MX (1)	MXPA04009535A (da)
NO (1)	NO20044698L (da)
NZ (1)	NZ536111A (da)
PL (1)	PL211160B1 (da)
PT (1)	PT1492539E (da)
UA (1)	UA79605C2 (da)
WO (1)	WO2003082298A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004071431A2 (en) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Method and composition for treating neurodegenerative disorders
MXPA06011969A (es) *	2004-04-14	2006-12-15	Warner Lambert Co	Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
WO2005123068A2 (en) *	2004-06-08	2005-12-29	Axonyx, Inc.	Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) *	2006-04-21	2006-05-31	Minster Res The Ltd	Mono and combination therapy
AU2007299726A1 (en) *	2006-09-22	2008-03-27	Braincells, Inc.	Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
WO2015089349A1 (en) *	2013-12-13	2015-06-18	Tabaczynski David A	Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet

2003
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en not_active Ceased
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko not_active Expired - Fee Related
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown

Also Published As

Publication number	Publication date
NO20044698L (no)	2004-10-29
IL164317A (en)	2010-04-29
EA013069B1 (ru)	2010-02-26
PL371551A1 (en)	2005-06-27
EP1492539A1 (en)	2005-01-05
AU2003226753A1 (en)	2003-10-13
CN100528164C (zh)	2009-08-19
AU2003226753B2 (en)	2007-06-28
IL164317A0 (en)	2005-12-18
JP2005525391A (ja)	2005-08-25
CA2480275A1 (en)	2003-10-09
EA200401295A1 (ru)	2005-02-24
WO2003082298A1 (en)	2003-10-09
CA2480275C (en)	2011-08-16
NZ536111A (en)	2006-03-31
EP1492539B1 (en)	2006-06-28
CN1642555A (zh)	2005-07-20
KR100986194B1 (ko)	2010-10-07
DE60306503D1 (de)	2006-08-10
CY1105545T1 (el)	2010-07-28
BR0308293A (pt)	2004-12-28
UA79605C2 (en)	2007-07-10
KR20040096608A (ko)	2004-11-16
PL211160B1 (pl)	2012-04-30
PT1492539E (pt)	2006-11-30
DE60306503T2 (de)	2007-06-21
ES2268393T3 (es)	2007-03-16
ATE331523T1 (de)	2006-07-15
MXPA04009535A (es)	2005-01-25
HK1079688A1 (zh)	2006-04-13

Publication	Publication Date	Title
DE60126980D1 (de)	2007-04-12	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO20053077L (no)	2005-09-22	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ATE269846T1 (de)	2004-07-15	N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
BG106095A (bg)	2002-06-28	Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
DE60316779D1 (de)	2007-11-22	Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MXPA05003253A (es)	2005-06-08	Nuevos derivados de pirimidinamida y el uso de los mismos.
ATE268174T1 (de)	2004-06-15	Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
BG104179A (en)	2000-10-31	Phanquinon administration for the treatment of the alzheimer's disease
DK1492539T3 (da)	2006-10-30	Statin-terapi til forögelse af kognitiv funktion
ATE499933T1 (de)	2011-03-15	Verwendung von betain zur behandlung von claudicatio intermittens
PT1147105E (pt)	2004-07-30	Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
ATE404192T1 (de)	2008-08-15	Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
EP1603595A4 (en)	2008-04-16	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
ATE293445T1 (de)	2005-05-15	Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
DK0707477T3 (da)	2000-05-15	Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
DE60122764D1 (de)	2006-10-12	Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE334675T1 (de)	2006-08-15	Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole